个人化医疗市场（按产品类型、技术、应用和最终用户划分）—2025-2030 年全球预测

个人化医疗市场规模预计在2024年达到4,254.8亿美元，2025年将成长至4,668.4亿美元，复合年增长率为9.92%，到2030年将达到7,506.9亿美元。

主要市场统计数据
基准年2024年	4254.8亿美元
预计2025年	4668.4亿美元
预计2030年	7506.9亿美元
复合年增长率（%）	9.92%

个人化医疗的创新正在重新定义患者照护并塑造下一代标靶治疗

近年来，个人化医疗已成为医疗创新的前沿，利用基因组学见解和精准诊断技术，根据患者的个别情况量身定制治疗方案。分子生物学的突破性进展使研究人员能够破解疾病的遗传基础，为针对特定生物标记的治疗方法铺平了道路。高通量定序和生物资讯学平台的进步促进了从传统的「一刀切」治疗方法转变为个人化治疗的转变。因此，临床医生现在可以识别出最能从特定治疗方法中受益的患者，从而提高有效率并最大限度地减少副作用。数位健康工具的整合进一步放大了这种潜力，使得能够持续监测患者的反应并制定适应性治疗方法。

基因定序和数位健康平台的快速发展正在改变全球个人化医疗的格局

过去十年，在基因组定序、数位健康整合和主导分析等技术突破的推动下，个人化医疗领域发生了翻天覆地的变化。全基因定序的成本自诞生以来大幅下降，不仅能洞察患者个体的突变特征，还能在临床实务中常规应用伴随诊断。同时，数位健康平台和穿戴式装置的普及促进了生物标记的远端监测，使医疗保健提供者能够近乎即时地检测治疗反应和病情进展。同时，监管机构，尤其是肿瘤学和罕见疾病领域的监管机构，已经引入了适应性框架，以加快标靶治疗的核准，体现了对以患者为中心的治疗途径的更广泛承诺。

2025 年美国关税升级将重塑全球个人化医疗市场的供应链与成本结构

美国近期推出的2025年关税调整政策，为个人化医疗价值链带来了新的复杂性。关税适用于高端试剂、定序设备和专用实验室耗材等关键零件，可能会提高投入成本，并扰乱既定的筹资策略。依赖跨国供应网路的公司现在必须应对成本波动，因为成本波动正在降低利润率，并迫使其进行策略调整。为此，一些产业相关人员已开始多元化其供应商基础，探索替代製造地，并将关键生产流程在地化，以减轻关税波动的影响。

产品类型、技术应用和最终用户的多样化细分揭示了个人化医疗的多样化机会

仔细观察市场细分，可以发现在产品类型、技术、应用和最终用户类别方面，个人化医疗生态系统呈现截然不同的动态。按产品类型划分，诊断方式涵盖伴随诊断、基因检测、影像学和分子诊断，每种方式在识别生物标记和对患者群体进行分层方面都发挥着关键作用。同时，治疗方案涵盖细胞和基因疗法、免疫疗法、单株抗体和常规药物，反映了针对潜在疾病机制的广泛方法。这种二分法凸显了诊断和治疗创新的互补性，即对疾病的准确表征可以转化为有针对性的干预策略。

不同的动力正在推动美洲、欧洲、中东和非洲以及亚太地区的个人化医疗

个人化医疗的区域趋势反映了美洲、欧洲、中东和非洲地区以及亚太地区不同的重点和发展轨迹。在美洲，对研究基础设施的强劲投资以及大型生物製药和诊断公司的入驻，正在推动基因组检测和标靶治疗的快速普及。强调基于价值的医疗服务的政策倡议，以及强大的临床试验点网络和报销途径，正在进一步加速市场扩张和新治疗方法的临床转化。

与领先创新者的策略伙伴关係加速个人化医疗生态系统的突破和竞争定位

个人化医疗领域的领先公司正透过对研发的策略投资和加速治疗创新的合作联盟来脱颖而出。一些生物医学公司已与基因组技术提供者建立独家合作伙伴关係，共同开发次世代定序方法，而其他公司则投资于专有的生物资讯平台，以增强分子数据的解读能力。这些策略倡议不仅增强了他们的内部能力，还在竞争格局中创造了差异化定位。

积极主动的策略和战术性投资可以帮助行业领导者利用新兴的个人化医疗趋势并克服监管障碍

为了充分利用个人化医疗的势头并应对不断变化的监管和商业环境，行业领导者应考虑一些积极主动的策略。首先，投资模组化和灵活的製造能力可以增强企业应对供应链中断和关税导致的成本波动的能力。在关键部件上设立本地生产中心，可以帮助企业确保供应的连续性，同时遵守区域贸易法规。同时，促进研发、监管和商业团队之间的多学科合作，可以简化将科学发现转化为市场化解决方案的过程，以最大限度地缩短患者受益的时间。

严格的资料收集、分析和检验方法是个人化医疗市场全面调查方法的基础

此项分析所依据的研究采用了严格的多阶段方法，以确保准确性和可靠性。首先，我们透过广泛的公开资讯来源（包括同行评审期刊、监管出版物和行业白皮书）进行了二次研究，以建立对技术趋势和市场动态的基础理解。此阶段还涉及审查专利资料库和临床试验註册中心，以确定个人化医疗领域的关键创新和开发平臺。

全面个人化医疗创新和策略性适应将推动永续成长并改变全球医疗保健服务模式。

随着个人化医疗从概念框架迈向临床实践，精准诊断、标靶治疗和数位健康平台的整合势必将改变全球患者的治疗结果。技术创新、策略性产业合作和自适应监管途径的整合，正为更有效、更有效率的医疗服务奠定基础。然而，对于寻求最大限度地发挥个人化介入潜力的相关人员来说，供应链不稳定、关税影响以及区域差异化应用等挑战仍然是重要的考虑因素。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

• 将人工智慧驱动的基因组分析整合到医疗网路的常规肿瘤治疗决策工作流程中
• 远端医疗和数位健康平台的扩展将实现远距药物基因组学咨询和个人化剂量建议
• 利用单细胞定序技术揭示患者特异性肿瘤异质性模式，以优化标靶治疗
• 开发针对个别新抗原谱的 mRNA 疫苗平台，用于下一代个人化癌症免疫治疗
• 新兴的多体学资料整合平台，结合蛋白质体学、代谢体学和转录组学，实现精准诊断和分层治疗
• 全球不断发展的法规结构，以支持基于即时生物标记回馈和患者分层的自适应临床试验
• 实施数位双胞胎技术来模拟患者对客製化治疗计画的复杂生理反应
• 基于 CRISPR 的基因编辑和递送系统在罕见单基因疾病个人化治疗的进展
• 整合人工智慧风险预测和生活方式改变建议的消费者基因检测服务的成长
• 製药公司与数位健康Start-Ups建立策略伙伴关係，共同开发个人化药物输送和依从性监测设备

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章：个人化医疗市场（依产品类型）

• 诊断
  • 伴随诊断
  • 基因检测
  • 影像学诊断
  • 分子诊断
• 治疗药物
  • 细胞和基因治疗
  • 免疫疗法
  • 单株抗体
  • 製药

第九章：个人化医疗市场（依技术）

• 生物资讯学
• 数位健康和​​人工智慧
• 基因组学和蛋白​​质组学
• 药物基因组学

第 10 章：个人化医疗市场（按应用）

• 心臟病学
  • 心律不整
  • 心臟衰竭
• 内分泌学
• 感染疾病
  • 细菌
  • 病毒性的
• 神经病学
  • 神经退化
  • 精神病学
• 肿瘤学
  • 造血系统恶性肿瘤
  • 固态肿瘤

第 11 章：个人化医疗市场（依最终用户划分）

• 学术研究机构
• 诊断实验室
• 医院和诊所

12.美洲个人化医疗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

第 13 章：欧洲、中东和非洲的个人化医疗市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

14. 亚太地区个人化医疗市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十五章 竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AMGEN INC
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biogen Inc
  • Danaher Corporation
  • Exact Sciences Corporation
  • GE Healthcare Technologies, Inc
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Pfizer Inc
  • QIAGEN NV
  • Roche Holding AG
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.
  • PierianDx, Inc.
  • CRISPR Therapeutics AG
  • bluebird bio, Inc.
  • Vertex Pharmaceuticals Incorporated

第十六章 研究人工智慧

第十七章 研究统计

第十八章 研究联络人

第十九章 研究报导

第二十章 附录

The Personalized Medicine Market was valued at USD 425.48 billion in 2024 and is projected to grow to USD 466.84 billion in 2025, with a CAGR of 9.92%, reaching USD 750.69 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 425.48 billion
Estimated Year [2025]	USD 466.84 billion
Forecast Year [2030]	USD 750.69 billion
CAGR (%)	9.92%

Innovations in Personalized Medicine Are Redefining Patient Care and Shaping the Next Generation of Targeted Therapeutics

In recent years, personalized medicine has emerged at the forefront of healthcare innovation, harnessing genomic insights and precision diagnostics to tailor treatments to individual patient profiles. Breakthroughs in molecular biology have enabled researchers to decode the genetic underpinnings of disease, paving the way for therapies that target specific biomarkers. This shift from traditional one-size-fits-all approaches to personalized interventions has been catalyzed by advancements in high-throughput sequencing and bioinformatics platforms, which deliver unprecedented resolution into the molecular drivers of pathology. As a result, clinicians can now identify patients who will benefit most from a given therapy, thereby improving efficacy rates and minimizing adverse effects. The integration of digital health tools further amplifies this potential, allowing for continuous monitoring of patient responses and adaptive treatment regimens.

Moreover, the convergence of data analytics and artificial intelligence has accelerated decision-making processes, enabling dynamic patient stratification and real-time adjustments to therapeutic protocols. Through collaborative efforts between research institutions, technology providers, and clinical stakeholders, personalized medicine is transitioning from theoretical promise to clinical reality. This introduction lays the groundwork for a comprehensive exploration of the key drivers, challenges, and emerging trends that define the evolving landscape of individualized healthcare solutions.

Rapid Advances in Genomic Sequencing and Digital Health Platforms Are Transforming the Personalized Medicine Landscape Globally

Over the past decade, the personalized medicine landscape has undergone transformative shifts driven by technological breakthroughs in genomic sequencing, digital health integration, and AI-driven analytics. The cost of whole-genome sequencing has plummeted dramatically since its inception, unlocking previously inaccessible insights into patient-specific mutation profiles and enabling the routine application of companion diagnostics in clinical practice. At the same time, the proliferation of digital health platforms and wearable devices has facilitated remote monitoring of biomarkers, empowering healthcare providers to detect treatment responses and disease progression in near real-time. In parallel, regulatory agencies have introduced adaptive frameworks that accelerate the approval of targeted therapies, particularly in oncology and rare disease domains, reflecting a broader commitment to patient-centric care pathways.

These developments have been complemented by strategic partnerships between biopharmaceutical companies and technology firms, fostering an ecosystem that leverages cross-disciplinary expertise to address complex therapeutic challenges. Collaborative research consortia now convene to standardize genomic data protocols and validate digital health endpoints, further solidifying the infrastructure needed for scalable implementation. In this context, value-based care models are increasingly being adopted, aligning reimbursement with treatment outcomes rather than volumetric service delivery. As personalized medicine continues to mature, these converging forces of innovation, policy evolution, and collaborative synergy are reshaping the healthcare paradigm, setting the stage for unprecedented levels of precision, efficiency, and patient empowerment.

Escalating United States Tariff Policies in 2025 Are Reshaping Supply Chains and Cost Structures in Personalized Medicine Markets Worldwide

Recent policy decisions regarding tariff adjustments in the United States for the year 2025 have introduced a new layer of complexity to the personalized medicine value chain. Tariffs applied to critical components such as high-grade reagents, sequencing equipment, and specialized laboratory consumables have the potential to increase input costs and disrupt established procurement strategies. Companies reliant on cross-border supply networks must now navigate a landscape where cost variances can erode profit margins and necessitate strategic recalibrations. In response, several industry players have begun diversifying their supplier base, seeking alternative manufacturing locations and localizing key production processes to mitigate exposure to tariff volatility.

Beyond direct cost implications, the tariff regime has also influenced collaborative research agreements, as international partners reassess the economic feasibility of joint ventures and technology transfers. Institutions in North America are exploring co-development frameworks with partners in tariff-exempt regions, optimizing for intellectual property protection and tax incentives. Simultaneously, small and medium-sized enterprises face heightened barriers to entry due to increased capital requirements and the need for more robust logistical planning. Despite these challenges, proactive stakeholder engagement with policy-makers and trade associations has emerged as a critical mechanism for advocating for tariff exemptions on life-saving and research-intensive products. Overall, the evolving tariff environment underscores the importance of agile supply chain strategies and cross-sector collaboration in sustaining the momentum of personalized medicine innovation.

Diverse Segmentation Across Product Types Technologies Applications and End Users Reveals Nuanced Opportunities in Personalized Medicine

An in-depth examination of market segmentation reveals distinct dynamics across product type, technology, application, and end user categories that collectively shape the personalized medicine ecosystem. Examining product type, diagnostics modalities span companion diagnostics, genetic testing, imaging diagnostics, and molecular diagnostics, each playing a pivotal role in identifying biomarkers and stratifying patient populations. Therapeutic solutions, on the other hand, encompass cell and gene therapy, immunotherapy, monoclonal antibodies, and conventional pharmaceuticals, reflecting a broad spectrum of approaches to target underlying disease mechanisms. This bifurcation underscores the complementary nature of diagnostic and therapeutic innovation, whereby precise disease characterization informs targeted intervention strategies.

When viewed through the lens of technology platforms, bioinformatics, digital health and artificial intelligence, genomics and proteomics, as well as pharmacogenomics emerge as critical enablers. Bioinformatics tools drive data interpretation, while digital health applications and AI algorithms facilitate real-time patient monitoring and adaptive treatment algorithms. Genomics and proteomics provide the molecular framework for identifying therapeutic targets, and pharmacogenomics informs drug selection based on individual metabolic profiles. These technologies function in concert to enhance the predictive power and personalized precision of clinical decision making.

Application areas further delineate the market's complexity. Cardiology divisions focus on arrhythmia and heart failure, endocrinology leverages hormone profiling, and infectious disease strategies address both bacterial and viral challenges. Neurology initiatives target neurodegenerative disorders and psychiatric conditions, while oncology efforts span hematologic malignancies and solid tumors. Finally, end user ecosystems include academic and research institutes, diagnostic laboratories, and hospitals and clinics, each serving as a crucial node in the translational continuum from discovery science to patient care. This multifaceted segmentation framework highlights the nuanced opportunities and challenges that stakeholders must navigate to drive personalized medicine forward.

Distinct Regional Dynamics Across Americas Europe Middle East Africa and Asia Pacific Are Driving Personalized Medicine Adoption Differently

Regional trends in personalized medicine reflect divergent priorities and developmental trajectories across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, strong investment in research infrastructure and the presence of leading biopharmaceutical and diagnostic companies drive rapid adoption of genomic testing and targeted therapies. Policy initiatives that emphasize value-based care, alongside a robust network of clinical trial sites and reimbursement pathways, further accelerate market expansion and clinical translation of novel therapies.

In contrast, the Europe Middle East and Africa region exhibits a heterogeneous landscape. Western Europe benefits from comprehensive healthcare coverage and regulatory harmonization through centralized agencies, fostering an environment conducive to the uptake of precision diagnostics and innovative treatment modalities. Conversely, emerging markets within the Middle East and Africa are characterized by nascent healthcare infrastructures and reliance on donor-funded programs, which presents both challenges and opportunities for scalable implementation of personalized medicine solutions.

Meanwhile, the Asia-Pacific region stands out for its large patient populations and growing focus on domestic manufacturing capabilities. Governments in key markets are investing in national genomic sequencing initiatives, and collaborative networks have been established to standardize data protocols and facilitate cross-border research. Additionally, partnerships between multinational corporations and local enterprises are enabling technology transfer and capacity building, positioning the region as a critical hub for future personalized medicine developments.

Leading Innovators and Strategic Collaborations Are Accelerating Breakthroughs and Competitive Positioning in the Personalized Medicine Ecosystem

Leading organizations in the personalized medicine arena are distinguishing themselves through strategic investment in research and development, as well as through collaborative alliances that accelerate therapeutic innovation. Several biomedical firms have secured exclusive partnerships with genomic technology providers to co-develop next-generation sequencing assays, while others have invested in proprietary bioinformatics platforms that enhance molecular data interpretation. These strategic maneuvers not only bolster internal capabilities but also create differentiated positioning in a highly competitive landscape.

Moreover, cross-sector collaborations are gaining momentum, with pharmaceutical companies partnering with digital health startups to integrate real-time patient monitoring into clinical trial designs. Such alliances enable more responsive trial protocols, reduce time to actionable insights, and improve patient retention rates. At the same time, emerging biotech companies are pursuing targeted acquisitions to expand their pipeline portfolios and gain access to novel therapeutic platforms, particularly in high-growth areas like cell and gene therapy. Meanwhile, diagnostic firms are forming consortia with academic institutions and contract research organizations to validate biomarkers and regulatory endpoints, reinforcing the evidentiary foundation required for market approval. By leveraging a combination of organic research efforts and external collaborations, these industry players are positioning themselves to lead the transition toward truly personalized healthcare solutions.

Proactive Strategies and Tactical Investments Will Empower Industry Leaders to Capitalize on Emerging Personalized Medicine Trends and Overcome Regulatory Hurdles

To capitalize on the momentum of personalized medicine and navigate the evolving regulatory and commercial landscape, industry leaders should consider several proactive strategies. First, investing in modular and flexible manufacturing capabilities will enhance resilience against supply chain disruptions and tariff-induced cost fluctuations. By adopting localized production hubs for critical components, organizations can ensure continuity of supply while maintaining compliance with regional trade regulations. Concurrently, fostering cross-disciplinary collaboration between R&D, regulatory affairs, and commercial teams will streamline the translation of scientific discoveries into market-ready solutions, minimizing time to patient benefit.

Second, integrating advanced data analytics and artificial intelligence into clinical development and patient engagement workflows will unlock new efficiencies. Machine learning models can predict patient responses and optimize trial design, while digital health platforms facilitate remote monitoring and adherence tracking. These technological investments will not only improve clinical outcomes but also generate real-world evidence that supports value-based reimbursement models.

Third, expanding strategic partnerships with academic centers, specialized contract research organizations, and technology providers will enhance access to cutting-edge expertise and infrastructure. Establishing co-development agreements and consortium-based research programs can spread risk and accelerate proof-of-concept validation. Additionally, engaging with policy-makers and industry associations to advocate for tariff exemptions on essential diagnostic and therapeutic components will help mitigate cost pressures.

Finally, prioritizing patient-centric frameworks-such as incorporating patient-reported outcomes and personalized engagement strategies-will strengthen adoption and long-term market success. By aligning commercialization strategies with patient needs and payer expectations, organizations can build sustainable value propositions that endure in a rapidly shifting healthcare environment.

Rigorous Data Collection Analysis and Validation Methodologies Underpinning the Comprehensive Research Approach in Personalized Medicine Markets

The research underpinning this analysis employs a rigorous multi-stage approach to ensure accuracy and reliability. Initially, secondary research was conducted across a broad spectrum of publicly available sources, including peer-reviewed journals, regulatory agency publications, and industry white papers, to establish a foundational understanding of technological trends and market dynamics. This phase also involved the review of patent databases and clinical trial registries to identify key innovations and developmental pipelines in personalized medicine.

Following this, primary research was executed through structured interviews with subject matter experts, including clinicians, technology providers, and regulatory consultants. These interviews offered qualitative insights into evolving adoption patterns, reimbursement challenges, and strategic priorities. Cross-functional dialogues with industry executives provided additional perspective on investment drivers and partnership opportunities.

Data triangulation techniques were then applied to reconcile findings from both primary and secondary sources. Quantitative data points were validated through multiple independent channels to strengthen confidence in the insights presented. Finally, an iterative validation process was conducted, where preliminary conclusions were reviewed by an external advisory panel to ensure objectivity and relevance. This comprehensive methodology ensures that the analysis reflects the latest evidence and expert perspectives, providing a robust foundation for strategic decision-making in the personalized medicine arena.

Integrated Personalized Medicine Innovations and Strategic Adaptations Are Poised to Drive Sustainable Growth and Transform Healthcare Delivery Models Worldwide

As personalized medicine advances from conceptual frameworks to clinical reality, the integration of precision diagnostics, targeted therapeutics, and digital health platforms is poised to transform patient outcomes globally. The convergence of technological innovation, strategic industry collaborations, and adaptive regulatory pathways has laid the groundwork for more effective and efficient care delivery. However, challenges such as supply chain volatility, tariff impacts, and heterogeneous regional adoption remain critical considerations for stakeholders seeking to maximize the potential of personalized interventions.

By embracing agile manufacturing strategies, fostering co-development partnerships, and leveraging advanced data analytics, organizations can navigate these complexities and achieve competitive differentiation. Simultaneously, prioritizing patient-centric approaches and cultivating evidence generation will bolster payer confidence and facilitate broader market access. As regional ecosystems continue to mature, opportunities for localized innovation and cross-border collaboration will further accelerate progress. Ultimately, the future of healthcare lies in the ability to tailor interventions to individual patient profiles, and those entities that successfully align scientific rigor with operational agility are best positioned to lead this transformative journey.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Integration of AI-driven genomic profiling in routine oncology treatment decision making workflows across healthcare networks
• 5.2. Expansion of telemedicine and digital health platforms enabling remote pharmacogenomic consultation and personalized dosing recommendations
• 5.3. Adoption of single-cell sequencing technologies to uncover patient-specific tumor heterogeneity patterns for targeted therapy optimization
• 5.4. Development of mRNA vaccine platforms tailored to individual neoantigen profiles for next-generation personalized cancer immunotherapy pipelines
• 5.5. Emergence of multiomics data integration platforms combining proteomics, metabolomics, and transcriptomics for precision diagnostics and treatment stratification
• 5.6. Regulatory frameworks evolving globally to support adaptive clinical trials driven by real-time biomarker feedback and patient stratification
• 5.7. Implementation of digital twin technology to simulate complex patient physiological responses to customized therapeutic regimens in silico
• 5.8. Advancements in CRISPR-based gene editing and delivery systems for personalized treatment of rare monogenic diseases
• 5.9. Growth of direct-to-consumer genetic testing services integrating AI-powered risk prediction and lifestyle modification recommendations
• 5.10. Strategic collaborations between pharmaceutical companies and digital health startups to co-develop personalized drug delivery and adherence monitoring devices

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Personalized Medicine Market, by Product Type

• 8.1. Introduction
• 8.2. Diagnostics
  • 8.2.1. Companion Diagnostics
  • 8.2.2. Genetic Testing
  • 8.2.3. Imaging Diagnostics
  • 8.2.4. Molecular Diagnostics
• 8.3. Therapeutics
  • 8.3.1. Cell & Gene Therapy
  • 8.3.2. Immunotherapy
  • 8.3.3. Monoclonal Antibodies
  • 8.3.4. Pharmaceuticals

9. Personalized Medicine Market, by Technology

• 9.1. Introduction
• 9.2. Bioinformatics
• 9.3. Digital Health & AI
• 9.4. Genomics & Proteomics
• 9.5. Pharmacogenomics

10. Personalized Medicine Market, by Application

• 10.1. Introduction
• 10.2. Cardiology
  • 10.2.1. Arrhythmia
  • 10.2.2. Heart Failure
• 10.3. Endocrinology
• 10.4. Infectious Diseases
  • 10.4.1. Bacterial
  • 10.4.2. Viral
• 10.5. Neurology
  • 10.5.1. Neurodegenerative
  • 10.5.2. Psychiatric
• 10.6. Oncology
  • 10.6.1. Hematologic Malignancies
  • 10.6.2. Solid Tumors

11. Personalized Medicine Market, by End User

• 11.1. Introduction
• 11.2. Academic & Research Institutes
• 11.3. Diagnostic Laboratories
• 11.4. Hospitals & Clinics

12. Americas Personalized Medicine Market

• 12.1. Introduction
• 12.2. United States
• 12.3. Canada
• 12.4. Mexico
• 12.5. Brazil
• 12.6. Argentina

13. Europe, Middle East & Africa Personalized Medicine Market

• 13.1. Introduction
• 13.2. United Kingdom
• 13.3. Germany
• 13.4. France
• 13.5. Russia
• 13.6. Italy
• 13.7. Spain
• 13.8. United Arab Emirates
• 13.9. Saudi Arabia
• 13.10. South Africa
• 13.11. Denmark
• 13.12. Netherlands
• 13.13. Qatar
• 13.14. Finland
• 13.15. Sweden
• 13.16. Nigeria
• 13.17. Egypt
• 13.18. Turkey
• 13.19. Israel
• 13.20. Norway
• 13.21. Poland
• 13.22. Switzerland

14. Asia-Pacific Personalized Medicine Market

• 14.1. Introduction
• 14.2. China
• 14.3. India
• 14.4. Japan
• 14.5. Australia
• 14.6. South Korea
• 14.7. Indonesia
• 14.8. Thailand
• 14.9. Philippines
• 14.10. Malaysia
• 14.11. Singapore
• 14.12. Vietnam
• 14.13. Taiwan

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Abbott Laboratories
  • 15.3.2. Agilent Technologies, Inc.
  • 15.3.3. AMGEN INC
  • 15.3.4. BGI Genomics Co., Ltd.
  • 15.3.5. Bio-Rad Laboratories, Inc.
  • 15.3.6. Bio-Techne Corporation
  • 15.3.7. Biogen Inc
  • 15.3.8. Danaher Corporation
  • 15.3.9. Exact Sciences Corporation
  • 15.3.10. GE Healthcare Technologies, Inc
  • 15.3.11. Guardant Health, Inc.
  • 15.3.12. Illumina, Inc.
  • 15.3.13. Myriad Genetics, Inc.
  • 15.3.14. Novartis AG
  • 15.3.15. Pfizer Inc
  • 15.3.16. QIAGEN N.V.
  • 15.3.17. Roche Holding AG
  • 15.3.18. Siemens Healthcare GmbH
  • 15.3.19. Thermo Fisher Scientific Inc.
  • 15.3.20. PierianDx, Inc.
  • 15.3.21. CRISPR Therapeutics AG
  • 15.3.22. bluebird bio, Inc.
  • 15.3.23. Vertex Pharmaceuticals Incorporated

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

• FIGURE 1. PERSONALIZED MEDICINE MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 14. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 16. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. PERSONALIZED MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 22. PERSONALIZED MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 23. PERSONALIZED MEDICINE MARKET: RESEARCHAI
• FIGURE 24. PERSONALIZED MEDICINE MARKET: RESEARCHSTATISTICS
• FIGURE 25. PERSONALIZED MEDICINE MARKET: RESEARCHCONTACTS
• FIGURE 26. PERSONALIZED MEDICINE MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. PERSONALIZED MEDICINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIGITAL HEALTH & AI, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIGITAL HEALTH & AI, BY REGION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENOMICS & PROTEOMICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENOMICS & PROTEOMICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 55. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 57. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 59. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 61. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY VIRAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 63. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 65. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 67. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 69. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PSYCHIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PSYCHIATRIC, BY REGION, 2025-2030 (USD MILLION)
• TABLE 71. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 73. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 75. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 77. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 79. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 81. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 83. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 85. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 87. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 89. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 90. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 91. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 92. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
• TABLE 93. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 94. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
• TABLE 95. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 96. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 97. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 98. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 99. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 100. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 101. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 103. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 105. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 106. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 107. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 108. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 109. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 111. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 112. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 113. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 114. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
• TABLE 115. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 116. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
• TABLE 117. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 118. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 119. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 120. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 121. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 122. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 123. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 124. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 125. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 126. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 127. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 128. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 129. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 130. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 131. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 132. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 133. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 134. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 135. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 136. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
• TABLE 137. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 138. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
• TABLE 139. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 140. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 141. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 142. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 143. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 144. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 145. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 146. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 147. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 148. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 149. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 150. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 151. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 152. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 153. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 154. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 155. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 156. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
• TABLE 157. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 158. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
• TABLE 159. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 160. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 161. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 162. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 163. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 164. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 165. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 166. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 167. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 168. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 169. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 170. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 171. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 172. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 173. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 174. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 175. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 176. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
• TABLE 177. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 178. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
• TABLE 179. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 180. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 181. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 182. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 183. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 184. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 185. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 186. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 187. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 188. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 189. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 190. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 191. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 192. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 193. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 194. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 195. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 196. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
• TABLE 197. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 198. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
• TABLE 199. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 200. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 201. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 202. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 203. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 204. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 205. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 206. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 207. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 208. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 209. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 210. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 211. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 212. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 227. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 229. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 231. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 233. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 236. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 238. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 240. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
• TABLE 241. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 242. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 243. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 244. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 245. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 246. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 247. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 248. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 249. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 250. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 251. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 252. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 253. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 254. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 255. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 256. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 257. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 258. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
• TABLE 259. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 260. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
• TABLE 261. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 262. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 263. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 264. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 265. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 266. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 267. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 268. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 269. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 270. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 271. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 272. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 273. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 274. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 275. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 276. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 277. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 278. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
• TABLE 279. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 280. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
• TABLE 281. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 282. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 283. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 284. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 285. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 286. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 287. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 288. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 289. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 290. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 291. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 292. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 293. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 294. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 295. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 296. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 297. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 298. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
• TABLE 299. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 300. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
• TABLE 301. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 302. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 303. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 304. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 305. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 306. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 307. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 308. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 309. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 310. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 311. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 312. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 313. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 314. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 315. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 316. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 317. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 318. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
• TABLE 319. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 320. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
• TABLE 321. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 322. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 323. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 324. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 325. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 326. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 327. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 328. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 329. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 330. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 331. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 332. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 333. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 334. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 335. SPAIN PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 336. SPAIN PERS